Abstract:Bispecific antibodies (bsAbs) are an emerging therapy in the treatment of large B-cell lymphomas (LBCLs). There is a gap in the research on the safety and efficacy of bsAbs in adults with LBCL, with current research focusing on the wider non-Hodgkin's lymphoma population. To address this research gap, we conducted a systematic review aiming to evaluate the safety and efficacy outcomes of bsAbs in adults with LBCL. A systematized search was conducted in PubMed, EMBASE, and CENTRAL on 10 April 2024. Interventional clinical trials were eligible for inclusion. Observational studies, reviews, and meta-analyses were excluded. According to the Revised Risk of Bias Assessment Tool for Nonrandomized Studies, the included studies were largely of a high quality for safety outcome reporting, but of mixed quality for efficacy outcome reporting. Due to the heterogeneity of the included studies, the results were discussed as a narrative synthesis. Nineteen early phase studies were evaluated in the final analysis, with a pooled sample size of 1332 patients. Nine bsAbs were investigated across the studies as monotherapy (nine studies) or in combination regimes (10 studies). The rates of cytokine release syndrome were variable, with any grade events ranging from 0 to 72.2%. Infection rates were consistently high across the reporting studies (38-60%). Cytopenias were found to be common, in particular, anemia (4.4-62%), thrombocytopenia (3.3-69%), and neutropenia (4.4-70%). Immune effector cell-associated neurotoxicity syndrome (ICANS) and grade ≥3 adverse events were not commonly reported. Promising efficacy outcomes were reported, with median overall response rates of 95-100% in the front-line and 36-91% in terms of relapsed/refractory disease. The results of this systematic review demonstrate that bsAbs are generally well-tolerated and effective in adults with LBCL. BsAbs appear to have superior tolerability, but inferior efficacy to CAR T-cell therapies in adults with LBCL. Future research on safety and efficacy should focus on evaluating adverse event timing and management, the impact on the patient's quality of life, the burden on the healthcare system, and overall survival outcomes.

Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma

Bispecific Antibody Treatment of Multiple Myeloma: Latest Updates from the 2022 ASH Annual Meeting

The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma

Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma

Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities

Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma

Redirecting T cells to hematological malignancies with bispecific antibodies

Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas

Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma

The value of bispecific antibodies in relapsed and refractory DLBCL

SOHO State of the Art Updates and Next Questions | Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma

Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs

Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma

Recent advances and future perspectives of T-cell engagers in lymphoid malignancies

Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting

Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data

Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting

The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review

Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma